| Status: Recommended | ||
Elbasvir/grazoprevir (Zepatier®) is recommended as an option for use within NHS Wales for the treatment of genotype 1 or 4 chronic hepatitis C (CHC) in paediatric patients 12 years of age and older who weigh at least 30 kg. |
||
|
||
Medicine details |
||
| Medicine name | elbasvir/grazoprevir (Zepatier®) | |
| Formulation | 50 mg/ 100 mg film-coated tablet | |
| Reference number | 4980 | |
| Indication | Treatment of chronic hepatitis C (CHC) in paediatric patients 12 years of age and older who weigh at least 30 kg |
|
| Company | Merck Sharp & Dohme Ltd | |
| BNF chapter | Infections | |
| Submission type | Licence extension for paediatric use | |
| Status | Recommended | |
| Advice number | 1222 | |
| AWMSG meeting date | 12/07/2022 | |
| Date of issue | 19/07/2022 | |
| Further information See also NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C in adults (published October 2016) |
||